{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T22:20:56Z","timestamp":1795126856462,"version":"4.10.3"},"reference-count":185,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Cutaneous melanoma remains a global health challenge. Although BRAF\/MEK-targeted therapies and immune checkpoint inhibitors (ICIs) have improved outcomes in advanced disease, durable responses remain difficult to achieve for most patients. Therapeutic resistance represents the central barrier to long-term disease control. This review comprehensively examines the molecular and immunologic mechanisms underlying melanoma resistance and integrates these insights with emerging pharmaceutical strategies designed to overcome them. We explore the genetic landscape of melanoma, including oncogenic alterations in BRAF, NRAS, NF1, CDKN2A, and PTEN, and explain how dysregulation of the MAPK and PI3K\/AKT\/mTOR signaling axes drives therapeutic escape. Phenotypic plasticity is discussed as a critical epigenetic driver of drug tolerance. The tumor microenvironment (TME) is examined as an active co-conspirator in resistance, encompassing immunosuppressive cell populations, cancer-associated fibroblasts, and metabolic competition. Resistance mechanisms to targeted therapy, including MAPK reactivation, bypass signaling, transcriptional reprogramming, and metabolic rewiring, are reviewed alongside tumor-intrinsic and tumor-extrinsic mechanisms of ICI resistance. Emerging therapeutic strategies are surveyed, including next-generation RAF and ERK inhibitors, dual-pathway blockade, and metabolic therapies targeting oxidative phosphorylation. Innovations in molecular imaging, liquid biopsy, and artificial intelligence-driven biomarker discovery are highlighted as pivotal tools for real-time resistance monitoring and adaptive treatment. By linking mechanistic insights with translational advances, this review advocates for combination strategies and adaptive clinical frameworks to achieve more durable disease control in melanoma.<\/jats:p>","DOI":"10.3390\/ph19091455","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T10:19:41Z","timestamp":1789381181000},"page":"1455","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic Resistance in Melanoma: Molecular Mechanisms and Emerging Pharmaceutical Strategies"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-9557-8787","authenticated-orcid":false,"given":"Nicolas","family":"Moussallem","sequence":"first","affiliation":[{"name":"School of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Awada","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut, Beirut P.O. Box 11-0236, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7638-8979","authenticated-orcid":false,"given":"Roy","family":"El Darzi","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut, Beirut P.O. Box 11-0236, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6477-5286","authenticated-orcid":false,"given":"Ali","family":"Tarhini","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut, Beirut P.O. Box 11-0236, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akel","family":"Khaled","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut, Beirut P.O. Box 11-0236, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3299-7772","authenticated-orcid":false,"given":"Christopher","family":"Ashy","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut, Beirut P.O. Box 11-0236, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9510-169X","authenticated-orcid":false,"given":"Wajih","family":"Nasr","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut, Beirut P.O. Box 11-0236, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4493-8830","authenticated-orcid":false,"given":"Amal","family":"El Masri","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut, Beirut P.O. Box 11-0236, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Saad","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut, Beirut P.O. Box 11-0236, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4142-1482","authenticated-orcid":false,"given":"Mohamad","family":"Itani","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut, Beirut P.O. Box 11-0236, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9053-5866","authenticated-orcid":false,"given":"Joe","family":"Rizkallah","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology, American University of Beirut, Beirut P.O. Box 11-0236, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7877-3086","authenticated-orcid":false,"given":"Nicole","family":"Charbel","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut, Beirut P.O. Box 11-0236, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuhair","family":"Hatahet","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut, Beirut P.O. Box 11-0236, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Saade","sequence":"additional","affiliation":[{"name":"Department of Dermatology, American University of Beirut, Beirut P.O. Box 11-0236, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5393-7751","authenticated-orcid":false,"given":"Jihane","family":"Abou Rahal","sequence":"additional","affiliation":[{"name":"Department of Dermatology, American University of Beirut, Beirut P.O. Box 11-0236, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2751-5154","authenticated-orcid":false,"given":"Firas","family":"Kreidieh","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut, Beirut P.O. Box 11-0236, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jamadermatol.2022.0160","article-title":"Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040","volume":"158","author":"Arnold","year":"2022","journal-title":"JAMA Dermatol."},{"key":"ref_2","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/CM9.0000000000003416","article-title":"Recent global patterns in skin cancer incidence, mortality, and prevalence","volume":"138","author":"Wang","year":"2025","journal-title":"Chin. Med. J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/CMR.0000000000000959","article-title":"Global trends in cutaneous malignant melanoma incidence and mortality","volume":"34","author":"Mignozzi","year":"2024","journal-title":"Melanoma Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.21.02229","article-title":"Long-Term Outcomes with Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients with Advanced Melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1038\/s41467-020-19075-3","article-title":"Combating acquired resistance to MAPK inhibitors in melanoma by targeting Abl1\/2-mediated reactivation of MEK\/ERK\/MYC signaling","volume":"11","author":"Tripathi","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.1038\/ncomms6712","article-title":"Low MITF\/AXL ratio predicts early resistance to multiple targeted drugs in melanoma","volume":"5","author":"Krijgsman","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1038\/s41467-023-36979-y","article-title":"The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma","volume":"14","author":"Lim","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1126\/science.aao3290","article-title":"The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients","volume":"359","author":"Matson","year":"2018","journal-title":"Science"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1158\/1535-7163.MCT-06-0084","article-title":"Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases","volume":"5","author":"Smalley","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Fang, X., Wang, S., and Fu, S. (2025). Dissecting the MAPK signaling landscape in malignant melanoma: From BRAF and NRAS mutations to precision combination therapies. Front. Cell Dev. Biol., 13.","DOI":"10.3389\/fcell.2025.1723066"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1610-0387.2006.05925.x","article-title":"A trip through the signaling pathways of melanoma","volume":"4","author":"Fensterle","year":"2006","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Kim, H.J., and Kim, Y.H. (2024). Molecular Frontiers in Melanoma: Pathogenesis, Diagnosis, and Therapeutic Advances. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25052984"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.21037\/tlcr-21-415","article-title":"Cyclin-dependent kinase 4 upregulation mediates acquired resistance of dabrafenib plus trametinib in BRAF V600E-mutated lung cancer","volume":"10","author":"Hirai","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.bcp.2010.04.029","article-title":"Targeting the MAPK pathway in melanoma: Why some approaches succeed and other fail","volume":"80","author":"Inamdar","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2217\/mmt.15.40","article-title":"NRAS mutant melanoma: An overview for the clinician for melanoma management","volume":"3","author":"Jenkins","year":"2016","journal-title":"Melanoma Manag."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/0092-8674(90)90151-4","article-title":"The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins","volume":"63","author":"Ballester","year":"1990","journal-title":"Cell"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"115365","DOI":"10.1016\/j.celrep.2025.115365","article-title":"The NF1 tumor suppressor regulates PD-L1 and immune evasion in melanoma","volume":"44","author":"Berry","year":"2025","journal-title":"Cell Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"165715","DOI":"10.1016\/j.bbadis.2020.165715","article-title":"Cell cycle regulators in cancer cell metabolism","volume":"1866","author":"Fajas","year":"2020","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Yang, T.T., Yu, S., Ke, C.K., and Cheng, S.T. (2023). The Genomic Landscape of Melanoma and Its Therapeutic Implications. Genes, 14.","DOI":"10.3390\/genes14051021"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"103863","DOI":"10.1016\/j.breast.2024.103863","article-title":"Cyclin-dependent kinase 4 and 6 inhibitors (CDK4\/6i): Mechanisms of resistance and where to find them","volume":"79","author":"Foffano","year":"2025","journal-title":"Breast"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Liu, J., Lin, J., Wang, X., Zheng, X., Gao, X., Huang, Y., Chen, G., Xiong, J., Lan, B., and Chen, C. (2022). CCND1 Amplification Profiling Identifies a Subtype of Melanoma Associated with Poor Survival and an Immunosuppressive Tumor Microenvironment. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.725679"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/0008-5472.CAN-23-1730","article-title":"PTEN Lipid Phosphatase Activity Suppresses Melanoma Formation by Opposing an AKT\/mTOR\/FRA1 Signaling Axis","volume":"84","author":"Xu","year":"2024","journal-title":"Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/jcmm.17699","article-title":"Tumour suppressor PTEN activity is differentially inducible by myo-inositol phosphates","volume":"27","author":"Grzymajlo","year":"2023","journal-title":"J. Cell. Mol. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e70054","DOI":"10.1111\/pcmr.70054","article-title":"The Roles of PTEN in Melanoma Suppression","volume":"38","author":"Parkman","year":"2025","journal-title":"Pigment. Cell Melanoma Res."},{"key":"ref_36","first-page":"5016","article-title":"axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase","volume":"11","author":"Frye","year":"1991","journal-title":"Mol. Cell. Biol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Wessely, A., Steeb, T., Berking, C., and Heppt, M.V. (2021). How Neural Crest Transcription Factors Contribute to Melanoma Heterogeneity, Cellular Plasticity, and Treatment Resistance. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22115761"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1038\/jid.2011.218","article-title":"Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase","volume":"131","author":"Sensi","year":"2011","journal-title":"J. Investig. Dermatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1038\/onc.2010.612","article-title":"Essential role of microphthalmia transcription factor for DNA replication, mitosis and genomic stability in melanoma","volume":"30","author":"Strub","year":"2011","journal-title":"Oncogene"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1101\/gad.406406","article-title":"Mitf regulation of Dia1 controls melanoma proliferation and invasiveness","volume":"20","author":"Carreira","year":"2006","journal-title":"Genes Dev."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.cell.2016.06.028","article-title":"EMT: 2016","volume":"166","author":"Nieto","year":"2016","journal-title":"Cell"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1755-148X.2010.00823.x","article-title":"A proliferative melanoma cell phenotype is responsive to RAF\/MEK inhibition independent of BRAF mutation status","volume":"24","author":"Zipser","year":"2011","journal-title":"Pigment. Cell Melanoma Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1111\/febs.16021","article-title":"Epithelial-to-mesenchymal-like transition events in melanoma","volume":"289","author":"Pedri","year":"2022","journal-title":"FEBS J."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.ccell.2018.03.017","article-title":"Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress","volume":"33","author":"Tsoi","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"114913","DOI":"10.5306\/wjco.v17.i1.114913","article-title":"Immune landscape of melanoma: Tumor microenvironment, resistance mechanisms, and predictive biomarkers","volume":"17","author":"Oliveira","year":"2026","journal-title":"World J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12943-023-01860-5","article-title":"Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: New opportunities in cancer immunotherapy and advances in clinical trials","volume":"22","author":"Zhang","year":"2023","journal-title":"Mol. Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Sikorski, H., \u017bmijewski, M.A., and Piotrowska, A. (2025). Tumor Microenvironment in Melanoma-Characteristic and Clinical Implications. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26146778"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","article-title":"The tumor microenvironment","volume":"30","author":"Anderson","year":"2020","journal-title":"Curr. Biol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.canlet.2017.12.032","article-title":"T regulatory cells mediate immunosuppresion by adenosine in peripheral blood, sentinel lymph node and TILs from melanoma patients","volume":"417","author":"Gerlini","year":"2018","journal-title":"Cancer Lett."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s10585-016-9814-x","article-title":"CD4+FOXP3+ T regulatory cells decrease and CD3+CD8+ T cells recruitment in TILs from melanoma metastases after electrochemotherapy","volume":"33","author":"Gerlini","year":"2016","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/s41590-022-01267-2","article-title":"The complex role of tumor-infiltrating macrophages","volume":"23","author":"Christofides","year":"2022","journal-title":"Nat. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Basak, U., Sarkar, T., Mukherjee, S., Chakraborty, S., Dutta, A., Dutta, S., Nayak, D., Kaushik, S., Das, T., and Sa, G. (2023). Tumor-associated macrophages: An effective player of the tumor microenvironment. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1295257"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"116657","DOI":"10.1016\/j.biopha.2024.116657","article-title":"In vitro study of cold atmospheric plasma-activated liquids inhibits malignant melanoma by affecting macrophage polarization through the ROS\/JAK2\/STAT1 pathway","volume":"175","author":"Chen","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s10456-024-09930-y","article-title":"Lactate secreted by glycolytic conjunctival melanoma cells attracts and polarizes macrophages to drive angiogenesis in zebrafish xenografts","volume":"27","author":"Yin","year":"2024","journal-title":"Angiogenesis"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Pizzurro, G.A., Liu, C., Bridges, K., Alexander, A.F., Huang, A., Baskaran, J.P., Ramseier, J., Bosenberg, M.W., Mak, M., and Miller-Jensen, K. (2021). 3D Model of the Early Melanoma Microenvironment Captures Macrophage Transition into a Tumor-Promoting Phenotype. Cancers, 13.","DOI":"10.3390\/cancers13184579"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1186\/s13046-023-02856-1","article-title":"Tumor cell-induced platelet aggregation accelerates hematogenous metastasis of malignant melanoma by triggering macrophage recruitment","volume":"42","author":"Chen","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Romano, V., Belviso, I., Venuta, A., Ruocco, M.R., Masone, S., Aliotta, F., Fiume, G., Montagnani, S., Avagliano, A., and Arcucci, A. (2021). Influence of Tumor Microenvironment and Fibroblast Population Plasticity on Melanoma Growth, Therapy Resistance and Immunoescape. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22105283"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"6159","DOI":"10.2174\/0929867329666220620124138","article-title":"Insights into Melanoma Fibroblast Populations and Therapeutic Strategy Perspectives: Friends or Foes?","volume":"29","author":"Avagliano","year":"2022","journal-title":"Curr. Med. Chem."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"101530","DOI":"10.1016\/j.jbc.2021.101530","article-title":"The interplay of fibroblasts, the extracellular matrix, and inflammation in scar formation","volume":"298","author":"Moretti","year":"2022","journal-title":"J. Biol. Chem."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Papaccio, F., Kovacs, D., Bellei, B., Caputo, S., Migliano, E., Cota, C., and Picardo, M. (2021). Profiling Cancer-Associated Fibroblasts in Melanoma. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22147255"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"9678","DOI":"10.1038\/s41467-024-53908-9","article-title":"Cancer-associated fibroblast subtypes modulate the tumor-immune microenvironment and are associated with skin cancer malignancy","volume":"15","author":"Forsthuber","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.omto.2022.01.003","article-title":"Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition","volume":"24","author":"Wenthe","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2340\/00015555-2568","article-title":"Clinical, Genetic and Innate Immunity Characteristics of Melanoma in Organ Transplant Recipients","volume":"97","author":"Brocard","year":"2017","journal-title":"Acta Derm. Venereol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.jid.2017.09.036","article-title":"Indoleamine 2,3-Dioxygenase Expression in Primary Cutaneous Melanoma Correlates with Breslow Thickness and Is of Significant Prognostic Value for Progression-Free Survival","volume":"138","author":"Rubel","year":"2018","journal-title":"J. Investig. Dermatol."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Najem, A., Soumoy, L., Sabbah, M., Krayem, M., Awada, A., Journe, F., and Ghanem, G.E. (2022). Understanding Molecular Mechanisms of Phenotype Switching and Crosstalk with TME to Reveal New Vulnerabilities of Melanoma. Cells, 11.","DOI":"10.3390\/cells11071157"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s11671-025-04303-w","article-title":"Emerging trends in synthesis, characterization, and mechanism of action of antibody-drug and antibody-nanoparticle conjugates","volume":"20","author":"Dixit","year":"2025","journal-title":"Discov. Nano"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"135","DOI":"10.5021\/ad.2013.25.2.135","article-title":"Insights into the Transforming Growth Factor-\u03b2 Signaling Pathway in Cutaneous Melanoma","volume":"25","author":"Perrot","year":"2013","journal-title":"Ann. Dermatol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"189443","DOI":"10.1016\/j.bbcan.2025.189443","article-title":"The CD39-CD73-adenosine axis: Master regulator of immune evasion and therapeutic target in pancreatic ductal adenocarcinoma","volume":"1880","author":"Liu","year":"2025","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1016\/j.ejca.2015.08.022","article-title":"Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms","volume":"51","author":"Johnson","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"5694","DOI":"10.1038\/ncomms6694","article-title":"Increased MAPK reactivation in early resistance to dabrafenib\/trametinib combination therapy of BRAF-mutant metastatic melanoma","volume":"5","author":"Long","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"102499","DOI":"10.1016\/j.ctrv.2022.102499","article-title":"Mechanisms of resistance to immune checkpoint inhibitors in melanoma: What we have to overcome?","volume":"113","author":"Ziogas","year":"2023","journal-title":"Cancer Treat. Rev."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/S0140-6736(20)32598-8","article-title":"Enhancing anti-tumour efficacy with immunotherapy combinations","volume":"397","author":"Larkin","year":"2021","journal-title":"Lancet"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1038\/s41467-024-47425-y","article-title":"Molecular patterns of resistance to immune checkpoint blockade in melanoma","volume":"15","author":"Lauss","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Turner, L.M., Terhaar, H., Jiminez, V., Anderson, B.J., Grant, E., and Yusuf, N. (2025). Tumor Microenvironmental Dynamics in Shaping Resistance to Therapeutic Interventions in Melanoma: A Narrative Review. Pharmaceuticals, 18.","DOI":"10.3390\/ph18081082"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ccr.2010.11.023","article-title":"Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R\/PI3K","volume":"18","author":"Villanueva","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"5590","DOI":"10.1038\/s41388-021-01911-5","article-title":"Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma","volume":"40","author":"Wang","year":"2021","journal-title":"Oncogene"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Chamcheu, J.C., Roy, T., Uddin, M.B., Banang-Mbeumi, S., Chamcheu, R.N., Walker, A.L., Liu, Y.Y., and Huang, S. (2019). Role and Therapeutic Targeting of the PI3K\/Akt\/mTOR Signaling Pathway in Skin Cancer: A Review of Current Status and Future Trends on Natural and Synthetic Agents Therapy. Cells, 8.","DOI":"10.3390\/cells8080803"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.tibs.2011.03.006","article-title":"The Ras-ERK and PI3K-mTOR pathways: Cross-talk and compensation","volume":"36","author":"Mendoza","year":"2011","journal-title":"Trends Biochem. Sci."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1535-7163.MCT-17-0349","article-title":"Rational Approaches for Combination Therapy Strategies Targeting the MAP Kinase Pathway in Solid Tumors","volume":"17","author":"Tolcher","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.celrep.2018.10.049","article-title":"BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association","volume":"25","author":"Vido","year":"2018","journal-title":"Cell Rep."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Pavelescu, L.A., Enache, R.M., Ro\u015fu, O.A., Profir, M., Cre\u0163oiu, S.M., and Gaspar, B.S. (2024). Predictive Biomarkers and Resistance Mechanisms of Checkpoint Inhibitors in Malignant Solid Tumors. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25179659"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1126\/science.aac4255","article-title":"Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy","volume":"350","author":"Sivan","year":"2015","journal-title":"Science"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.semcancer.2022.06.005","article-title":"Targeting inflamed and non-inflamed melanomas: Biological background and clinical challenges","volume":"86","author":"Indini","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12943-017-0684-x","article-title":"PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation","volume":"16","author":"Tutuka","year":"2017","journal-title":"Mol. Cancer"},{"key":"ref_85","first-page":"665","article-title":"Drug resistance in targeted cancer therapies with RAF inhibitors","volume":"4","author":"Degirmenci","year":"2021","journal-title":"Cancer Drug Resist."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1158\/2159-8290.CD-18-1321","article-title":"Targeting Alterations in the RAF-MEK Pathway","volume":"9","author":"Yaeger","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Vanni, I., Tanda, E.T., Spagnolo, F., Andreotti, V., Bruno, W., and Ghiorzo, P. (2020). The Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape. Front. Mol. Biosci., 7.","DOI":"10.3389\/fmolb.2020.00113"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1200\/JCO.19.02654","article-title":"Phase I, Open-Label, Dose-Escalation\/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients with Solid Tumors","volume":"38","author":"Desai","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Mechahougui, H., Gutmans, J., Gouasmi, R., Smekens, L., and Friedlaender, A. (2025). BRAF Targeting Across Solid Tumors: Molecular Aspects and Clinical Applications. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26083757"},{"key":"ref_90","unstructured":"Khaddour, K., Kurn, H., Patel, P., and Zito, P.M. (2026). Vemurafenib. StatPearls, StatPearls Publishing."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1158\/1535-7163.MCT-17-0456","article-title":"Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1\/2 Inhibitor BVD-523 (Ulixertinib)","volume":"16","author":"Germann","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1158\/2159-8290.CD-17-1119","article-title":"First-in-Class ERK1\/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study","volume":"8","author":"Sullivan","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1158\/2767-9764.CRC-24-0036","article-title":"A Phase II Study of ERK Inhibition by Ulixertinib (BVD-523) in Metastatic Uveal Melanoma","volume":"4","author":"Buchbinder","year":"2024","journal-title":"Cancer Res. Commun."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"M\u00fcller, S.M., and J\u00fccker, M. (2024). The Functional Roles of the Src Homology 2 Domain-Containing Inositol 5-Phosphatases SHIP1 and SHIP2 in the Pathogenesis of Human Diseases. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25105254"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/s41591-018-0052-4","article-title":"An inhibitor of oxidative phosphorylation exploits cancer vulnerability","volume":"24","author":"Molina","year":"2018","journal-title":"Nat. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ccr.2013.02.003","article-title":"Oncogenic BRAF regulates oxidative metabolism via PGC1\u03b1 and MITF","volume":"23","author":"Haq","year":"2013","journal-title":"Cancer Cell"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"7481","DOI":"10.1074\/jbc.RA120.013366","article-title":"IACS-010759, a potent inhibitor of glycolysis-deficient hypoxic tumor cells, inhibits mitochondrial respiratory complex I through a unique mechanism","volume":"295","author":"Tsuji","year":"2020","journal-title":"J. Biol. Chem."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41591-022-02103-8","article-title":"Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: Phase I trials","volume":"29","author":"Yap","year":"2023","journal-title":"Nat. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.molonc.2015.08.003","article-title":"Resistance to BRAF inhibitors induces glutamine dependency in melanoma cells","volume":"10","author":"Baenke","year":"2016","journal-title":"Mol. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Nassief, G., Anaeme, A., Moussa, K., Mansour, A.N., and Ansstas, G. (2024). Recent Advancements in Cell-Based Therapies in Melanoma. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25189848"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Knight, A., Karapetyan, L., and Kirkwood, J.M. (2023). Immunotherapy in Melanoma: Recent Advances and Future Directions. Cancers, 15.","DOI":"10.3390\/cancers15041106"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/s41419-023-05961-3","article-title":"TIGIT, a novel immune checkpoint therapy for melanoma","volume":"14","author":"Tang","year":"2023","journal-title":"Cell Death Dis."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s11912-021-01104-z","article-title":"Next-Generation Immunotherapy Approaches in Melanoma","volume":"23","author":"Buchanan","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"200773","DOI":"10.1016\/j.omton.2024.200773","article-title":"Promising immunotherapy targets: TIM3, LAG3, and TIGIT joined the party","volume":"32","author":"Lu","year":"2024","journal-title":"Mol. Ther. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1200\/JCO.24.01124","article-title":"Three-Year Overall Survival with Nivolumab Plus Relatlimab in Advanced Melanoma from RELATIVITY-047","volume":"43","author":"Tawbi","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jaad.2019.03.012","article-title":"Expression of lymphocyte-activating gene 3 and T-cell immunoreceptor with immunoglobulin and ITIM domains in cutaneous melanoma and their correlation with programmed cell death 1 expression in tumor-infiltrating lymphocytes","volume":"81","author":"Lee","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"4756","DOI":"10.1200\/JCO.23.00172","article-title":"Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results","volume":"41","author":"Diab","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Yang, Y., and Lundqvist, A. (2020). Immunomodulatory Effects of IL-2 and IL-15; Implications for Cancer Immunotherapy. Cancers, 12.","DOI":"10.3390\/cancers12123586"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1136\/jitc-2024-010650","article-title":"Selective activation of interleukin-2\/interleukin-15 receptor signaling in tumor microenvironment using paired bispecific antibodies","volume":"13","author":"Montorfani","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.18632\/oncotarget.27772","article-title":"Targeting an engineered cytokine with interleukin-2 and interleukin-15 activity to the neovasculature of solid tumors","volume":"11","author":"Mortensen","year":"2020","journal-title":"Oncotarget"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1200\/EDBK_79437","article-title":"And Now for Something Completely Different: Immunotherapy Beyond Checkpoints in Melanoma","volume":"40","author":"Glitza","year":"2020","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s40257-025-00957-5","article-title":"Tumor-Infiltrating Lymphocyte Therapy for the Treatment of Metastatic Melanoma","volume":"26","author":"Tsai","year":"2025","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1200\/JCO-25-00765","article-title":"Long-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients with Advanced Melanoma: A 5-Year Analysis of the C-144-01 Study","volume":"43","author":"Medina","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Rabbani, S.A., El-Tanani, M., El-Tanani, Y., Kumar, R., Sharma, S., Khan, M.A., Parvez, S., Aljabali, A.A.A., Matalka, M.I., and Rizzo, M. (2025). Advances in Adoptive Cell Therapies in Cancer: From Mechanistic Breakthroughs to Clinical Frontiers and Overcoming Barriers. Med. Sci., 13.","DOI":"10.3390\/medsci13030190"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"e473440","DOI":"10.1200\/EDBK-25-473440","article-title":"Autologous T-Cell Therapies in Solid Tumor Malignancies: Current Landscape and Future Opportunities","volume":"45","author":"Reinhorn","year":"2025","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"102353","DOI":"10.1016\/j.xcrm.2025.102353","article-title":"CAR-T cells in solid tumors: Challenges and breakthroughs","volume":"6","author":"Escobar","year":"2025","journal-title":"Cell Rep. Med."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Boti, M.A., Diamantopoulos, M.A., and Scorilas, A. (2025). RNA-Targeting Techniques: A Comparative Analysis of Modern Approaches for RNA Manipulation in Cancer Research and Therapeutics. Genes, 16.","DOI":"10.3390\/genes16101168"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"897348","DOI":"10.1155\/2013\/897348","article-title":"Gene therapy for advanced melanoma: Selective targeting and therapeutic nucleic acids","volume":"2013","author":"Viola","year":"2013","journal-title":"J. Drug Deliv."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"zcag002","DOI":"10.1093\/narcan\/zcag002","article-title":"Identification of siRNA silencing TGF\u03b21 and VEGFR2 and utility of the combination in targeting immune modulation and angiogenesis in treating melanoma in vivo","volume":"8","author":"Wang","year":"2026","journal-title":"NAR Cancer"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"543","DOI":"10.18632\/oncotarget.28447","article-title":"Deconstructing the role of MALAT1 in MAPK-signaling in melanoma: Insights from antisense oligonucleotide treatment","volume":"14","author":"Feichtenschlager","year":"2023","journal-title":"Oncotarget"},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Bidram, M., Zhao, Y., Shebardina, N.G., Baldin, A.V., Bazhin, A.V., Ganjalikhany, M.R., Zamyatnin, A.A., and Ganjalikhani-Hakemi, M. (2021). mRNA-Based Cancer Vaccines: A Therapeutic Strategy for the Treatment of Melanoma Patients. Vaccines, 9.","DOI":"10.3390\/vaccines9101060"},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Bafaloukos, D., Gazouli, I., Koutserimpas, C., and Samonis, G. (2023). Evolution and Progress of mRNA Vaccines in the Treatment of Melanoma: Future Prospects. Vaccines, 11.","DOI":"10.3390\/vaccines11030636"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): A randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Sisk, C.K., Turner, L.M., Meraj, S., and Yusuf, N. (2026). Advances in mRNA-Based Melanoma Vaccines: A Narrative Review of Lipid Nanoparticle and Dendritic Cell Delivery Platforms. Cells, 15.","DOI":"10.3390\/cells15020099"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ymthe.2024.01.005","article-title":"The landscape of nanoparticle-based siRNA delivery and therapeutic development","volume":"32","author":"Moazzam","year":"2024","journal-title":"Mol. Ther."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Paulo, E.P.A., Cabral, L.G.S., Poyet, J.L., and Maria, D.A. (2026). Nanotechnology in Cutaneous Oncology: The Role of Liposomes in Targeted Melanoma Therapy. Molecules, 31.","DOI":"10.3390\/molecules31020344"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"9078","DOI":"10.1158\/0008-5472.CAN-08-2397","article-title":"Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA","volume":"68","author":"Villares","year":"2008","journal-title":"Cancer Res."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"100048","DOI":"10.1016\/j.pscia.2024.100048","article-title":"Targeted drug conjugates in cancer therapy: Challenges and opportunities","volume":"2","author":"Jia","year":"2024","journal-title":"Pharm. Sci. Adv."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/PPO.0000000000000627","article-title":"Strategies for Mitigating Antibody-Drug Conjugate Related Adverse Events for Precision Therapy","volume":"28","author":"Gouda","year":"2022","journal-title":"Cancer J."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Hoffmann, R.M., Crescioli, S., Mele, S., Sachouli, E., Cheung, A., Chui, C.K., Andriollo, P., Jackson, P.J.M., Lacy, K.E., and Spicer, J.F. (2020). A Novel Antibody-Drug Conjugate (ADC) Delivering a DNA Mono-Alkylating Payload to Chondroitin Sulfate Proteoglycan (CSPG4)-Expressing Melanoma. Cancers, 12.","DOI":"10.3390\/cancers12041029"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1007\/s11864-022-01018-3","article-title":"Antibody-Drug Conjugates for Melanoma and Other Skin Malignancies","volume":"23","author":"Goodman","year":"2022","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s40268-024-00473-7","article-title":"Antibody-Drug Conjugates in the Pipeline for Treatment of Melanoma: Target and Pharmacokinetic Considerations","volume":"24","author":"Lami","year":"2024","journal-title":"Drugs R D"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"e432462","DOI":"10.1200\/EDBK_432462","article-title":"Breaking the Mold: Trailblazing Melanoma Therapy Beyond Checkpoint Through Innovative Approaches","volume":"44","author":"Kidwai","year":"2024","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_135","first-page":"34","article-title":"The next frontier in antibody-drug conjugates: Challenges and opportunities in cancer and autoimmune therapy","volume":"8","author":"Zhou","year":"2025","journal-title":"Cancer Drug Resist."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","article-title":"Antibody-Drug Conjugates (ADCs): Current and future biopharmaceuticals","volume":"18","author":"Wang","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Buyukgolcigezli, I., Tenekeci, A.K., and Sahin, I.H. (2025). Opportunities and Challenges in Antibody-Drug Conjugates for Cancer Therapy: A New Era for Cancer Treatment. Cancers, 17.","DOI":"10.20944\/preprints202502.1917.v1"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1541-7786.MCR-19-0582","article-title":"Antibody-Drug Conjugates: A Comprehensive Review","volume":"18","author":"Khongorzul","year":"2020","journal-title":"Mol. Cancer Res."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"118953","DOI":"10.1016\/j.biopha.2025.118953","article-title":"Hydrogel-based delivery of cytokines in cancer immunotherapy: Latest evidence and therapeutic outcomes","volume":"194","author":"Khorramdelazad","year":"2026","journal-title":"Biomed. Pharmacother."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.omto.2019.10.007","article-title":"Oncolytic Viruses for Cancer Therapy: Barriers and Recent Advances","volume":"15","author":"Zheng","year":"2019","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1186\/s12951-025-03613-6","article-title":"Hydrogels as advanced drug delivery platforms for cancer immunotherapy: Promising innovations and future outlook","volume":"23","author":"Mohammadzadeh","year":"2025","journal-title":"J. Nanobiotechnol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jconrel.2023.04.028","article-title":"Sustained release hydrogel for durable locoregional chemoimmunotherapy for BRAF-mutated melanoma","volume":"357","author":"Kim","year":"2023","journal-title":"J. Control. Release"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"114724","DOI":"10.1016\/j.addr.2023.114724","article-title":"Recent advances in long-acting drug delivery systems for anticancer drug","volume":"194","author":"Pacheco","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"181","DOI":"10.4103\/0971-5916.195024","article-title":"PLGA-loaded nanomedicines in melanoma treatment: Future prospect for efficient drug delivery","volume":"144","author":"Das","year":"2016","journal-title":"Indian J. Med. Res."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"37950","DOI":"10.1038\/s41598-025-20253-w","article-title":"NT-I7, a novel long-acting interleukin-7, promotes anti-PD-1 efficacy in an autologous humanized melanoma model","volume":"15","author":"Phoon","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"16071","DOI":"10.1038\/natrevmats.2016.71","article-title":"Designing hydrogels for controlled drug delivery","volume":"1","author":"Li","year":"2016","journal-title":"Nat. Rev. Mater."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"eabl6339","DOI":"10.1126\/sciadv.abl6339","article-title":"Overcoming differential tumor penetration of BRAF inhibitors using computationally guided combination therapy","volume":"8","author":"Ng","year":"2022","journal-title":"Sci. Adv."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"45402","DOI":"10.1021\/acsomega.4c07415","article-title":"Enhanced Delivery and Potency of Chemotherapeutics in Melanoma Treatment via Magnetite Nanobioconjugates","volume":"9","author":"Quezada","year":"2024","journal-title":"ACS Omega"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1021\/acs.chemrev.9b00738","article-title":"ImmunoPET: Concept, Design, and Applications","volume":"120","author":"Wei","year":"2020","journal-title":"Chem. Rev."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s00259-018-4171-4","article-title":"FDG PET\/CT for assessing tumour response to immunotherapy: Report on the EANM symposium on immune modulation and recent review of the literature","volume":"46","author":"Aide","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1038\/onc.2012.345","article-title":"MAP kinase signaling and inhibition in melanoma","volume":"32","author":"Sullivan","year":"2013","journal-title":"Oncogene"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1158\/0008-5472.CAN-18-2762","article-title":"Resistance to MAPK Inhibitors in Melanoma Involves Activation of the IGF1R-MEK5-Erk5 Pathway","volume":"79","year":"2019","journal-title":"Cancer Res."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ejca.2016.04.005","article-title":"Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?","volume":"62","author":"Welsh","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.2967\/jnumed.120.241901","article-title":"Synthesis of the PET Tracer (124)I-Trametinib for MAPK\/ERK Kinase Distribution and Resistance Monitoring","volume":"61","author":"Pratt","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1158\/1078-0432.CCR-18-1485","article-title":"A PET Imaging Strategy for Interrogating Target Engagement and Oncogene Status in Pancreatic Cancer","volume":"25","author":"Henry","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/s41591-018-0255-8","article-title":"89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer","volume":"24","author":"Bensch","year":"2018","journal-title":"Nat. Med."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/CMR.0000000000001050","article-title":"Programmed death ligand-1 PET imaging in patients with melanoma: A pilot study","volume":"35","author":"Mauguen","year":"2025","journal-title":"Melanoma Res."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1158\/0008-5472.CAN-15-1707","article-title":"An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy","volume":"76","author":"Mok","year":"2016","journal-title":"Cancer Res."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"6146","DOI":"10.1073\/pnas.1502609112","article-title":"Noninvasive imaging of immune responses","volume":"112","author":"Rashidian","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_160","first-page":"720","article-title":"CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of 89Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody","volume":"63","author":"Farwell","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41698-024-00567-0","article-title":"A multiparameter liquid biopsy approach allows to track melanoma dynamics and identify early treatment resistance","volume":"8","author":"Scaini","year":"2024","journal-title":"npj Precis. Oncol."},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Slusher, N., Jones, N., and Nonaka, T. (2024). Liquid biopsy for diagnostic and prognostic evaluation of melanoma. Front. Cell Dev. Biol., 12.","DOI":"10.3389\/fcell.2024.1420360"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"8750","DOI":"10.1038\/s41467-024-52923-0","article-title":"Tumour-informed liquid biopsies to monitor advanced melanoma patients under immune checkpoint inhibition","volume":"15","author":"Schroeder","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1111\/exd.14901","article-title":"The dynamics of circulating tumour DNA (ctDNA) during treatment reflects tumour response in advanced melanoma patients","volume":"32","author":"Mannino","year":"2023","journal-title":"Exp. Dermatol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"100295","DOI":"10.1016\/j.jlb.2025.100295","article-title":"Circulating tumor DNA monitoring in advanced mutated melanoma (LIQUID-MEL)","volume":"8","author":"Gianmarco","year":"2025","journal-title":"J. Liq. Biopsy"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"155410","DOI":"10.1016\/j.prp.2024.155410","article-title":"Exosomal miR-19a derived from melanoma cell promotes the vemurafenib resistance of malignant melanoma through directly targeting LRIG1 to reactivate AKT and MAPK pathway","volume":"260","author":"Luan","year":"2024","journal-title":"Pathol. Res. Pract."},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"Fatima, S., Ma, Y., Safrachi, A., Haider, S., Spring, K.J., Vafaee, F., Scott, K.F., Roberts, T.L., Becker, T.M., and de Souza, P. (2022). Harnessing Liquid Biopsies to Guide Immune Checkpoint Inhibitor Therapy. Cancers, 14.","DOI":"10.3390\/cancers14071669"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/bjc.2012.306","article-title":"Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis","volume":"107","author":"Weide","year":"2012","journal-title":"Br. J. Cancer"},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Andhari, S., Farmaha, J., Vashisht, A., Vashisht, V., Woodall, J., Mondal, A.K., Jones, K., Pandita, A., Shafi, G., and Uttarwar, M. (2026). Real-Time Therapy Response Monitoring Using Surface Biomarkers on Circulating Tumor Cells. Cancers, 18.","DOI":"10.3390\/cancers18030391"},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Yadav, P., Rajendrasozhan, S., Lajimi, R.H., Patel, R.R., Heymann, D., and Prasad, N.R. (2025). Circulating tumor cell markers for early detection and drug resistance assessment through liquid biopsy. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1494723"},{"key":"ref_172","doi-asserted-by":"crossref","unstructured":"Kloten, V., Lampignano, R., Krahn, T., and Schlange, T. (2019). Circulating Tumor Cell PD-L1 Expression as Biomarker for Therapeutic Efficacy of Immune Checkpoint Inhibition in NSCLC. Cells, 8.","DOI":"10.3390\/cells8080809"},{"key":"ref_173","first-page":"269","article-title":"A Potential \u201cAnti-Warburg Effect\u201d in Circulating Tumor Cell-mediated Metastatic Progression?","volume":"16","author":"Jiang","year":"2023","journal-title":"Aging Dis."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1189\/jlb.1013565","article-title":"Histone deacetylase isoforms regulate innate immune responses by deacetylating mitogen-activated protein kinase phosphatase-1","volume":"95","author":"Jeong","year":"2014","journal-title":"J. Leukoc. Biol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma","volume":"165","author":"Hugo","year":"2016","journal-title":"Cell"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1101\/gad.290940.116","article-title":"Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma","volume":"31","author":"Falletta","year":"2017","journal-title":"Genes Dev."},{"key":"ref_177","first-page":"13","article-title":"Diagnostic and prognostic biomarkers in melanoma","volume":"7","author":"Weinstein","year":"2014","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1470-2045(22)00687-8","article-title":"Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAF(V600) mutation-positive advanced melanoma (IMspire150): Second interim analysis of a multicentre, randomised, phase 3 study","volume":"24","author":"Ascierto","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1200\/JCO.22.01763","article-title":"Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients with Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134","volume":"41","author":"Atkins","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41467-023-44475-6","article-title":"Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial","volume":"15","author":"Ascierto","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2024.11.006","article-title":"Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"36","author":"Amaral","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"100444","DOI":"10.1016\/j.xgen.2023.100444","article-title":"Predicting patient outcomes after treatment with immune checkpoint blockade: A review of biomarkers derived from diverse data modalities","volume":"4","author":"Liu","year":"2024","journal-title":"Cell Genom."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"31908","DOI":"10.1038\/s41598-025-15830-y","article-title":"An attention-based mRNA transformer network for accurate prediction of melanoma response to immune checkpoint inhibitors","volume":"15","author":"Yin","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"e84263","DOI":"10.7554\/eLife.84263","article-title":"A survey of open questions in adaptive therapy: Bridging mathematics and clinical translation","volume":"12","author":"West","year":"2023","journal-title":"eLife"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.annonc.2023.10.125","article-title":"Artificial intelligence for predictive biomarker discovery in immuno-oncology: A systematic review","volume":"35","author":"Prelaj","year":"2024","journal-title":"Ann. Oncol."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/9\/1455\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T10:37:28Z","timestamp":1789382248000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/9\/1455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":185,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["ph19091455"],"URL":"https:\/\/doi.org\/10.3390\/ph19091455","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]}}}